 |
|
|
| |
A Phase 2a Study Evaluating the Multi-dose Activity of ARB-1467 in HBeAg-Positive and -Negative
Virally Suppressed Subjects with Hepatitis B
|
| |
| |
Reported by Jules Levin
EASL 2017 April 19-23 Amsterdam Netherlands
Adrian Streinu-Cercel1, Ed Gane2, Wendy Cheng3, William Sievert4, Stuart Roberts5, Sang Hoon Ahn6, Yoon Jun Kim7, Kosh Agarwal8, William Symonds9, Patricia Mendez9
1Carol Davila University of Medicine and Pharmacy, Prof. Dr. Matei Bals National Institute for Infectious Diseases, Bucharest, Romania; 2Auckland Clinical Studies Limited, Auckland, New Zealand; 3Royal Perth Hospital and Linear Research, Perth, Australia; 4Monash Health, Melbourne, Australia; 5The Alfred, Melbourne, Australia; 6Yonsei University College of Medicine,
Seoul, South Korea; 7Seoul National University College of Medicine, Seoul, South Korea; 8King's College Hospital Foundation Trust, London, United Kingdom; 9Arbutus Biopharma Corporation, Burnaby, Canada.
|
| |
|
|
|
|
|
